戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e) analogue is located to the 5' side of the cisplatin-DNA adduct.
2 2-7 s-1 ), with larger effects closer to the cisplatin-DNA adduct.
3 so the propeller twisted base pairs near the cisplatin-DNA adduct.
4 same substrate containing a single 1,2d(GpG) cisplatin-DNA adduct.
5 h repair proteins function as a detector for cisplatin DNA adducts.
6 he presence of DNA-distorting damage such as cisplatin-DNA adducts.
7 ct of the 5'-group, favoring left canting in cisplatin-DNA adducts.
8 y contributes to the accumulative pattern of cisplatin-DNA adducts.
9 ing of rhRPA to DNA containing site-specific cisplatin-DNA adducts.
10 and other proteins that bind specifically to cisplatin-DNA adducts.
11 y for many DNA-distorting lesions, including cisplatin-DNA adducts.
12 ts Pol eta in a manner distinct from that of cisplatin-DNA adducts.
13 n testes, uniquely blocks excision repair of cisplatin-DNA adducts, 1,2-intrastrand cross-links, to p
14           Proteins that discriminate between cisplatin-DNA adducts and oxaliplatin-DNA adducts are th
15 teins can block excision repair of the major cisplatin-DNA adducts and suggest that such an activity
16  are discussed with respect to the repair of cisplatin-DNA adducts and the role of DNA-PK in coordina
17 or a 1,3d(GXG), intermediate for a 1,2d(GpG) cisplatin-DNA adduct, and least for an undamaged duplex
18 mplications for the biological processing of cisplatin-DNA adducts are discussed.
19                         For nuclear genomes, cisplatin-DNA adducts are enriched within promoters and
20                                      Because cisplatin-DNA adducts block RNA polymerase II unless rem
21 and in terms of the selective recognition of cisplatin-DNA adducts by HMG-domain proteins.
22  DNA substrate containing a single 1,2d(GpG) cisplatin-DNA adduct compared with an undamaged DNA subs
23 lity to translocate on duplex DNA containing cisplatin-DNA adducts compared to control, undamaged dup
24 in Csa(-/-) and Csb(-/-) mice fail to remove cisplatin-DNA adducts efficiently in vitro; and unlike X
25  futile cycles of translesion synthesis past cisplatin-DNA adducts followed by removal of the newly s
26  were not associated with a change in either cisplatin-DNA adduct formation or repair over time.
27 , and there was no increase in the extent of cisplatin-DNA adduct formation.
28 n resistance but do not reduce the extent of cisplatin-DNA adduct formation.
29 in-damaged DNA correlated with the extent of cisplatin-DNA adduct formation.
30 hat is bound with Ku at a DNA end containing cisplatin-DNA adducts has a reduced catalytic rate compa
31        The binding of HMG-domain proteins to cisplatin-DNA adducts has been proposed to divert these
32              However, the genomic pattern of cisplatin-DNA adducts has remained unknown owing to the
33 B4 specifically inhibits repair of the major cisplatin-DNA adducts in TGCT cells by using the human T
34 at DNA binding was essentially unaffected by cisplatin-DNA adducts in the presence or absence of DNA-
35 The potential role of HMG-1 in the repair of cisplatin-DNA adducts is discussed.
36 2-d(ApG) intrastrand cross-link, a prevalent cisplatin-DNA adduct, is excised by the excinuclease fro
37                      These data suggest that cisplatin-DNA adducts may compete with specific DNA sequ
38 f cis-diamminedichloroplatinum(II) (cis-DDP, cisplatin) DNA adducts over >3000 nucleotides was carrie
39  of duplex DNA substrates with site-specific cisplatin-DNA adducts placed in three different orientat
40                                 In addition, cisplatin-DNA adduct position resulted in differing degr
41 i with a specific DNA strand orientation and cisplatin-DNA adduct position.
42 s without a functional ERCC-1 do not perform cisplatin-DNA adduct repair.
43                        Replicative bypass of cisplatin DNA adducts requires the cooperative actions o
44            The crystal structure of the same cisplatin-DNA adduct reveals not only the bent DNA duple
45  least an order of magnitude more tightly to cisplatin-DNA adducts than to unmodified DNA.
46 th hSRY and the hSRY-HMG domain for a single cisplatin-DNA adduct were comparable to those for the pu

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。